Glenbrook Capital在2月12日购买了7 956股Senestech股份,将其股份增加到618 310股。 Glenbrook Capital bought 7,956 Senestech shares on Feb. 12, boosting its stake to 618,310 shares.

2026年2月12日,Senestech(SNES)的主要股东Glenbrook资本管理公司(Glenbrook Capital Management)购买了7 956股,每股1.72美元,股份增加了1.30%,达到618 310股,价值约106万美元。 On February 12, 2026, Glenbrook Capital Management, a major shareholder of Senestech (SNES), bought 7,956 shares at $1.72 each, increasing its stake by 1.30% to 618,310 shares, valued at about $1.06 million. 购买情况在证交会档案中披露。 The purchase was disclosed in an SEC filing. 在此之前,该公司于2月初还购置了几套其他股票,在1月30日至2月13日期间共购买约80 000股,约合166 182美元。 This follows several other acquisitions by the firm in early February, totaling around 80,000 shares bought between January 30 and February 13 for approximately $166,182. Senestech是一家开发非致命性鼠类控制解决办法的生物技术公司,市场上限为1 044万美元,股票价格接近2000美元。 Senestech, a biotech company developing non-lethal rodent control solutions, has a market cap of $10.44 million and a stock price near $2.00. 分析员的前景好坏参半,有共识的“稳住”评级。 Analysts have a mixed outlook, with a consensus “Hold” rating.